Hospice News November 7, 2024
Amedisys Inc.’s (Nasdaq: AMED) hospice segment has seen headwinds impact admissions growth as the company awaits its pending acquisition by the UnitedHealth Group (NYSE: UNH) subsidiary Optum.
The company’s hospice segment revenue reached $207.9 million in Q3, a rise from $200.2 million during the same period last year.
Gross margin for the hospice segment fell slightly to 42.9% from 44.3% year-over-year. Hospice results were in part impacted by a -4% decrease in patient admissions and a 0.5% rise in average daily census volumes. Other factors included rising hospice care delivery costs such as investments in clinical staffing and higher compensation and benefit costs, among others, the company reported.
“Rate increases and home health volume growth were offset by raises, wage...
Today's Sponsors
Today's Sponsor